Academic Journal
Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus.
| Τίτλος: | Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus. |
|---|---|
| Συγγραφείς: | Contieri R; Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', Naples, Italy., Gontero P; Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza at Molinette Hospital and University of Turin, Turin, Italy., Hurle R; Department of Urology, Humanitas Clinical and Research Institute IRCCS, Milan, Italy., Afferi L; Department of Urology, Kantonsspital Aarau, Aarau, Switzerland., Albisinni S; Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy., Babjuk M; Department of Urology, Teaching Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Birtle A; University of Manchester, Manchester, UK.; University of Central Lancashire, Preston, UK., Black P; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Brausi M; Department of Urology, Hesperia Hospital, Modena, Italy., Bruins M; Department of Urology, Zuyderland Medisch Centrum, Sittard/Heerlen, The Netherlands., Čapoun O; Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia., Carrion A; Department of Urology, Vall Hebron Hospital, Autonomous University of Barcelona, Barcelona, Spain., Catto J; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK., Choudhury A; Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Cimadamore A; Institute of Pathological Anatomy, Department of Medicine, University of Udine, Udine, Italy., Comperat E; Department of Pathology, Medical University Vienna, Vienna, Austria., Daneshmand S; Department of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA., D'andrea D; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Del Giudice F; Department of Maternal Infant and Urologic Sciences, 'Sapienza' University of Rome, Policlinico Umberto I Hospital, Rome, Italy., Escrig JLD; Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain., Hensley P; Department of Urology, University of Kentucky College of Medicine, Lexington, KY, USA., Krajewski W; University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, Wroclaw, Poland., Laukhtina E; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Li R; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Liedberg F; Division of Urological Research, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden., Lotan Y; University of Texas Southwestern, Dallas, TX, USA., Marcq G; Department of Urology, CHU Lille, Lille UniversityUniversity, Lille, France., Mariappan P; Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK., Mari A; Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy., Martini A; Department of Urology, University of Cincinnati College of Medicine, Cincinnati, OH, USA., Lecomte AM; Department of Urology, Hôpital Saint-Louis AP-HP, Université Paris Cité, Paris, France., Meijer R; Department of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands., Mir MC; Department of Urology, Mount Sinai Icahn School of Medicine, Elmhurst/Queens Hospitals, New York, NY, USA., Mori K; Department of Urology, Jikei University School of Medicine, Tokyo, Japan., Moschini M; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Mostafid H; Department of Urology, Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK., O'Donnell M; Department of Urology, University of Iowa, Iowa City, IA, USA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA., Palou J; Department of Urology, Fundació Puigvert, Barcelona, Spain., Panebianco V; Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy., Perdonà S; Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', Naples, Italy., Porten S; Department of Urology, University of California San Francisco, San Francisco, CA, USA., Psutka S; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Rink M; Department of Urology, Marienkrankenhaus Hamburg, Hamburg, Germany., Roupret M; GRC n°5, Predictive Onco-Urology, Ap-Hp, Hôpital Pitié-Salpêtrière Urology, Sorbonne Université, Paris, France., Seisen T; GRC n°5, Predictive Onco-Urology, Ap-Hp, Hôpital Pitié-Salpêtrière Urology, Sorbonne Université, Paris, France., Soloway M; Urologic Oncology, Memorial Physician Group, Division of Urology, Memorial Healthcare System, Aventura, FL, USA., Soukup V; Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia., Steinberg G; Department of Urology, Rush University Medical Center, Chicago, IL, USA., Stenzl A; Department of Urology, Eberhard-Karls-University, Tübingen, Germany., Teoh JY; Department of Surgery, S.H. Ho Urology Centre, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China., Tully K; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany., van der Heijden T; Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands., van Rhijn BWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Witjes A; Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands., Xylinas E; Department of Urology, Bichat Claude Bernard Hospital, Paris University, Paris, France., Kamat AM; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pradere B; Department of Urology, La Croix Du Sud Hospital, Quint-Fonsegrives, France., Mertens LS; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. l.mertens@nki.nl. |
| Πηγή: | Nature reviews. Urology [Nat Rev Urol] 2026 Oct; Vol. 23 (10), pp. 691-696. Date of Electronic Publication: 2026 Apr 01. |
| Τύπος έκδοσης: | Consensus Statement; Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500082 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-4820 (Electronic) Linking ISSN: 17594812 NLM ISO Abbreviation: Nat Rev Urol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : Nature Pub. Group |
| Ιατρικοί όροι (MeSH): | Non-Muscle Invasive Bladder Neoplasms*/therapy , Non-Muscle Invasive Bladder Neoplasms*/pathology , Urinary Bladder Neoplasms*/pathology , Urinary Bladder Neoplasms*/therapy , Watchful Waiting*/methods , Delphi Technique*, Humans ; Consensus ; Neoplasm Grading |
| Περίληψη: | Standard management for recurrent low-grade non-muscle-invasive bladder cancer (LG-NMIBC) often involves a substantial treatment burden, which is not justified by the relatively indolent course of the disease, prompting a need for de-intensification strategies. Active surveillance (AS) is an alternative approach aimed at reducing overtreatment in selected patients. However, the broader adoption of AS is hindered by a lack of standardized protocols for patient selection, monitoring and intervention. To address this gap, we conducted an international, two-round Delphi consensus among 51 bladder cancer experts to establish foundational statements for the use of AS. Consensus was achieved on 20 statements, providing clear recommendations for terminology; inclusion and exclusion criteria; follow-up monitoring; and exit criteria. This Delphi consensus provides the first expert-driven framework to standardize the clinical application of AS for LG-NMIBC. These statements could guide current clinical practice and unify the design of future trials. (© 2026. Springer Nature Limited.) |
| Competing Interests: | Competing interests: The authors declare no competing interests. |
| References: | Eur Urol. 2024 Aug;86(2):148-163. (PMID: 38614820) J Urol. 2018 Feb;199(2):401-406. (PMID: 28847481) JAMA Netw Open. 2022 Mar 1;5(3):e223050. (PMID: 35302627) J Urol. 2016 Oct;196(4):1021-9. (PMID: 27317986) Urology. 2019 Mar;125:131-137. (PMID: 30366045) Eur Urol Oncol. 2024 Dec;7(6):1497-1503. (PMID: 38906794) J Urol. 2003 Aug;170(2 Pt 1):438-41. (PMID: 12853794) Eur Urol. 2025 Jun;87(6):683-696. (PMID: 40118739) Eur Urol Oncol. 2025 Feb;8(1):179-189. (PMID: 39218742) Urol Oncol. 2016 Apr;34(4):165.e19-23. (PMID: 26687318) Eur Urol Oncol. 2022 Apr;5(2):251-255. (PMID: 34059485) Eur Urol. 2006 Feb;49(2):303-6; discussion 306-7. (PMID: 16413659) Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. (PMID: 16442208) J Urol. 2008 Jan;179(1):87-90; discussion 90. (PMID: 17997444) Eur Urol Focus. 2023 Jul;9(4):564-566. (PMID: 37059619) J Urol. 2014 Jan;191(1):20-7. (PMID: 23973937) J Clin Epidemiol. 2014 Apr;67(4):401-9. (PMID: 24581294) |
| Entry Date(s): | Date Created: 20260401 Date Completed: 20260930 Latest Revision: 20261008 |
| Update Code: | 20261008 |
| DOI: | 10.1038/s41585-026-01137-8 |
| PMID: | 41922791 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1759-4820 |
|---|---|
| DOI: | 10.1038/s41585-026-01137-8 |